Testing an allergy medication for people with COPD

Plain-English translation of NCT07059091 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called omalizumab — an injection already used to treat allergies — to see if it can help people with COPD who are also allergic to things in their home like pets, dust mites, or cockroaches. The study will compare people who receive the medication with people who receive a placebo (a harmless saline injection) to understand whether this treatment can reduce COPD symptoms and exacerbations in people with both conditions.

Many people with COPD also have indoor allergies, and those allergens may trigger or worsen their breathing problems. This trial exists to find out if treating the allergy component with this medication might help improve COPD control and reduce flare-ups.

Do you qualify?

You likely qualify if…

you are 40 years or older
you have been diagnosed with COPD and are currently taking at least two long-acting inhaled medications
you have a history of significant cigarette smoking (more than 10 pack-years)
you have evidence of allergy to at least one common household allergen (cat, dog, dust mites, cockroaches, or mice) confirmed by testing
the allergen you are allergic to is actually present in your home dust in measurable amounts

You likely don't qualify if…

you have asthma as a current diagnosis
you are currently receiving allergy shots or similar allergen immunotherapy
you have a history of severe allergic reactions (anaphylaxis) to medications or foods
you have had lung surgery or a procedure to reduce lung volume in the past year
you are currently taking other biologic medications (monoclonal antibodies) for any condition

What participation looks like

If you qualify and are randomized into the study, you will receive either the active medication or a placebo injection on a regular schedule determined by your weight and allergy level. You will visit the research site for injections and to have your COPD symptoms monitored over the course of the trial. The study team will check whether your breathing improves, whether you have fewer flare-ups, and how well you tolerate the treatment.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(23 sites)

United States

University of Alabama, Birmingham, Alabama

University of Arizona- Tuscon, Tucson, Arizona

University of San Francisco, San Francisco, California

National Jewish Health, Denver, Colorado

University of Florida, Jacksonville, Florida